


The CHAMPS

- CHAMPS is the acronym for the


[Redacted]

Study



The CHAMPS

2




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute [redacted] event with MRI [redacted]

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the landmark clinical trial (four words) IV steroid dosing

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing

The CHAMPS




- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
- Result: Avonex treatment produced a % reduction in the onset of CDMS at 3 years

The CHAMPS



- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
- Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years



The CHAMPS

- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
- Result: Avonex treatment produced a 44% reduction in the onset of **CDMS** at 3 years


What does **CDMS** stand for?



The CHAMPS

- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
- Result: Avonex treatment produced a 44% reduction in the onset of **CDMS** at 3 years


What does **CDMS** stand for?
Clinically definite multiple sclerosis



The CHAMPS

- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to corticosteroid dosing

| | |
|---|-----|
| <i>Cumulative probability of MS at three years:</i> | |
| Placebo group: | 50% |
| Avonex group: | 28% |
- Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years



The CHAMPS

- CHAMPS is the acronym for the *Controlled High-Risk Subject Avonex MS Prevention Study*
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β -1a
- In addition to corticosteroid dosing, received the Optic Neu *Cumulative probability of MS at three years:*
 Placebo group: 50%
 Avonex group: 35%
- Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years

The CHAMPS



Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--
--

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV** steroid dosing
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years

The CHAMPS



Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--IFN β -1b

--Glatiramer acetate

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV** steroid dosing
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years

The CHAMPS



Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--IFN β -1b

--Glatiramer acetate

What are their brand names?

--IFN β -1b:

--Glatiramer acetate:

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV** steroid dosing
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years

The CHAMPS



Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

- IFN β -1b
- Glatiramer acetate

What are their brand names?

- IFN β -1b: **Betaseron**
- Glatiramer acetate: **Copaxone**

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV** steroid dosing
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years



The CHAMPS

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--IFN β -1b

--Glatiramer acetate

What are their brand names?


--IFN β -1b: **Betaseron**

--Glatiramer acetate: **Copaxone**

*Together, what are **Avonex**, **Betaseron** and **Copaxone** called?*

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV steroid dosing**
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years

The CHAMPS



Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--IFN β -1b

--Glatiramer acetate

What are their brand names?

--IFN β -1b: **Betaseron**

--Glatiramer acetate: **Copaxone**

*Together, what are **A**vonex, **B**etaseron and **C**opaxone called?*

The '**ABC meds**' for MS

- **Avonex is interferon β -1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV steroid dosing**
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years